Standardising use of oral liquid medicines to treat tuberculosis

摘要

We are writing to highlight recent work carried out to improve the provision of anti-tuberculosis oral liquid medicines in the UK. Almost two-thirds of hospital pharmacy departments in the UK have reported problems accessing antituberculosis treatments (International Journal of Tuberculosis and Lung Disease 15(6):754-760). The fragility of the supply chain is a significant problem because interruptions in treatment will contribute to the known risk of resistance, including multidrug-resistant tuberculosis (MDR-TB), and the more recent emergence of extensively drug-resistant tuberculosis (XDR-TB).